Nuria Garcia-Fernandez

Dr. Nuria Garcia-Fernandez

1. Nephrology Department, Clínica Universidad de Navarra. Avenida Pio XII, 36. Pamplona 31008, Navarra, Spain
+2
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2018 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
NSNicholas M Selby
Nicholas M Selby
PBPeter J Blankestijn
Peter J Blankestijn
PBPeter Boor
Peter Boor
CCChristian Combe
Christian Combe
KEKai-Uwe Eckardt
Kai-Uwe Eckardt
SSSteven Sourbron
Steven Sourbron
Functional renal magnetic resonance imaging (MRI) has seen a number of recent advances, and techniques are now available that can generate quantitative imaging biomarkers with the potential to improve the management of kidney disease. Such biomarkers are sensitive to changes in renal blood flow, tissue perfusion, oxygenation and microstructure (including inflammation and fibrosis), processes that are important in a range of renal diseases including chronic kidney disease. However, several challenges remain to move these techniques towards clinical adoption, from technical validation through biological and clinical validation, to demonstration of cost-effectiveness and regulatory qualification. To address these challenges, the European Cooperation in Science and Technology Action PARENCHIMA was initiated in early 2017. PARENCHIMA is a multidisciplinary pan-European network with an overarching aim of eliminating the main barriers to the broader evaluation, commercial exploitation and clinical use of renal MRI biomarkers. This position paper lays out PARENCHIMA’s vision on key clinical questions that MRI must address to become more widely used in patients with kidney disease, first within research settings and ultimately in clinical practice. We then present a series of practical recommendations to accelerate the study and translation of these techniques.

8 February 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NGNuria Garcia-Fernandez
Nuria Garcia-Fernandez
CCConxita Jacobs Cachá
Conxita Jacobs Cachá
JMJosé María Mora-Gutiérrez
José María Mora-Gutiérrez
AVAnder Vergara
Ander Vergara
JOJosune Orbe
Josune Orbe
MSMaria Jose Soler
Maria Jose Soler
Around the world diabetic kidney disease (DKD) is the main cause of chronic kidney disease (CKD), which is characterized by mesangial expansion, glomerulosclerosis, tubular atrophy, and interstitial fibrosis. The hallmark of the pathogenesis of DKD is an increased extracellular matrix (ECM) accumulation causing thickening of the glomerular and tubular basement membranes, mesangial expansion, sclerosis, and tubulointerstitial fibrosis. The matrix metalloproteases (MMPs) family are composed of zinc-dependent enzymes involved in the degradation and hydrolysis of ECM components. Several MMPs are expressed in the kidney; nephron compartments, vasculature and connective tissue. Given their important role in DKD, several studies have been performed in patients with DKD proposing that the measurement of their activity in serum or in urine may become in the future markers of early DKD. Studies from diabetic nephropathy experimental models suggest that a balance between MMPs levels and their inhibitors is needed to maintain renal homeostasis. This review focuses in the importance of the MMPs within the kidney and their modifications at the circulation, kidney and urine in patients with DKD. We also cover the most important studies performed in experimental models of diabetes in terms of MMPs levels, renal expression and its down-regulation effect.

6 April 2017 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
JMJosé María Mora-Gutiérrez
José María Mora-Gutiérrez
NGNuria Garcia-Fernandez
Nuria Garcia-Fernandez
MRM. Fernanda Slon Roblero
M. Fernanda Slon Roblero
JPJosé A Páramo
José A Páramo
JEJavier Escalada
Javier Escalada
MFMaría. A. Fernández-Seara
María. A. Fernández-Seara

1 December 2008 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
GBGuillermina Barril
Guillermina Barril
ICInmaculada Castillo
Inmaculada Castillo
MAMaría Dolores Arenas
María Dolores Arenas
MEMario Espinosa
Mario Espinosa
JGJuan Garcia-Valdecasas
Juan Garcia-Valdecasas
VTVicente Carren[Combining Tilde]O
Vicente Carren[Combining Tilde]O
Occult hepatitis C virus (HCV) infection (i.e., detectable HCV-RNA in the liver or peripheral blood mononuclear cells) in the absence of both serum HCV-RNA and anti-HCV antibodies has not been investigated in hemodialysis patients. In this study, real-time PCR and in situ hybridization was used to test for the presence of genomic and antigenomic HCV-RNA in peripheral blood mononuclear cells of 109 hemodialysis patients with abnormal levels of liver enzymes. Occult HCV infection, determined by the presence of genomic HCV-RNA, was found in 45% of the patients; 53% of these patients had ongoing HCV replication, indicated by the presence of antigenomic HCV-RNA. Patients with occult HCV infection had spent a significantly longer time on hemodialysis and had significantly higher mean alanine aminotransferase levels during the 6 mo before study entry. Logistic regression analysis revealed that mortality was associated with age >60 yr (odds ratio 3.30; 95% confidence interval 1.05 to 10.33) and the presence of occult HCV infection (odds ratio 3.84; 95% confidence interval 1.29 to 11.43). In conclusion, the prevalence of occult HCV infection is high among hemodialysis patients with persistently abnormal values of liver enzymes of unknown cause. The clinical significance of occult HCV infection in these patients requires further study.

1 October 2002 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
MTMarta Todeschini
Marta Todeschini
DMDaniela Macconi
Daniela Macconi
NGNuria Garcia-Fernandez
Nuria Garcia-Fernandez
MGMarina Ghilardi
Marina Ghilardi
AAAgostina Anabaya
Agostina Anabaya
MNMarina Noris
Marina Noris

2 March 2011 in Blood Purification
Verified
Journal Article
Closed access
NGNuria Garcia-Fernandez
Nuria Garcia-Fernandez
JPJosé Ramón Pérez-Valdivieso
José Ramón Pérez-Valdivieso
Maira Bes-RastrolloMaira Bes-Rastrollo
Maira Bes-Rastrollo
MVMarc Vives
Marc Vives
JLJavier Lavilla
Javier Lavilla
OCOn Behalf Of The Gedrcc (Grupo Español de Disfunción Renal En Cirugía Cardiaca)
On Behalf Of The Gedrcc (Grupo Español de Disfunción Renal En Cirugía Cardiaca)
Background: The optimal time to initiate renal replacement therapy (RRT) in cardiac surgery-associated acute kidney injury (CSA-AKI) is unknown. Evidence suggests that the early use of RRT in critically ill patients is associated with improved outcomes. We studied the effects of time to initiation of RRT on outcome in patients with CSA-AKI. Methods: This was a retrospective observational multicenter study (24 Spanish hospitals). We analyzed data on 203 patients who required RRT after cardiac surgery in 2007. The cohort was divided into 2 groups based on the time at which RRT was initiated: in the early RRT group, therapy was initiated within the first 3 days after cardiac surgery; in the late group, RRT was begun after the 3rd day. Multivariate nonconditional logistic and linear regression models were used to adjust for potential confounders. Results: In-hospital mortality was significantly higher in the late RRT group compared with early RRT patients (80.4 vs. 53.2%; p < 0.001; adjusted odds ratio of 4.1, 95% CI: 1.6–10.0). Also, patients in the late RRT group had longer adjusted hospital stays by 11.6 days (95% CI: 1.4–21.9) and higher adjusted percentage increases in creatinine at discharge compared with baseline by 67.7% (95% CI: 28.5–106.4). Conclusions: Patients who undergo early initiation of RRT after CSA-AKI have improved survival rates and renal function at discharge and decreased lengths of hospital stay.